JM Gamble

JM is a Clinical Associate Professor at the University of Waterloo in the School of Pharmacy and holds adjunct appointments with the University of Toronto and McMaster University. He completed his doctoral studies in Public Health Sciences at the University of Alberta and pharmacy training. JM is a pharmacist and epidemiologist who leads a research program in drug safety and effectiveness. His team focuses on understanding the real-world use and effects of diabetes therapies. Moreover, Dr. Gamble’s lab is interested in exploring methods to communicate drug information to facilitate evidence informed decision making for patients, health provider, and policy-makers. He has contributed to over 90 peer-reviewed manuscripts and received funding from the Canadian Institutes of Health Research (CIHR), Diabetes Canada, the Heart and Stroke Foundation of Canada, and the Canadian Foundation for Innovation. JM continues to practice as a pharmacist in a family health team based diabetes clinic.

• Post-marketing drug safety and effectiveness

• Comparative safety and effectiveness

• Pharmacoepidemiology

• Diabetes health outcomes

• Drug information science

• Clinical Pharmacy and Pharmacy Practice

Dr. Gamble conducts drug safety and effectiveness research using epidemiologic methods. His team generates new evidence of drug effects through knowledge syntheses and observational drug effect studies in the area of diabetes pharmacotherapy., Dr. Gamble’s other research interests include knowledge translation of drug information, evidence-based monitoring of medications, and pharmaceutical policy evaluation.

• 2012 PhD Public Health Science (University of Alberta)

• 2008 MSc Clinical Epidemiology (University of Alberta)

• 2005 BSc Pharmacy (University of Alberta)

• 2001 BSc Biology (Lakehead University)

• 2017 Primary Healthcare Researcher of the Year, Memorial University

• 2013-2018 New Investigator Award, Canadian Institutes of Health Research

• 2013-2018 Clinician Scientist Award, Canadian Diabetes Association

• 2005 Dean George A Burbidge Memorial Award, Canadian Pharmacists Association

• Member, CIHR College of Reviewers (Sept. 2017 – present)

• Board Member, Canadian Association of Population Therapeutics (Nov 2015 - present)

• Member, Diabetes Canada Clinical & Scientific Section (2009 – present)

• Member, International Society for Pharmacoepidemiology (2008 – present)

• HLTH 472 - Independent Study
  • Taught in 2026
• PHARM 222 - Integrated Patient Focused Care 3
  • Taught in 2021, 2022, 2023, 2025, 2026
• PHARM 290 - Seminars in Pharmacy 1
  • Taught in 2026
• PHARM 401 - Independent Study 2
  • Taught in 2024
• PHARM 611 - Special Topics in Pharmacy Practice
  • Taught in 2022, 2023
• PHARM 654 - Critical Appraisal and Evidence-Based Practice
  • Taught in 2021
• PHARM 656 - Analysis of Quantitative Health Care Data
  • Taught in 2024

* Only courses taught in the past 5 years are displayed.

• Abu-Ashour W., Delaney S., Farrell A., Gamble J.-M., Hawboldt J., and Sale J.E.M., Incidence of Major Depressive Disorder Relapse and Effectiveness of Pharmacologic and Psychological Interventions in Primary Car, Canadian Journal of Psychiatry, Volume 70, 529-551, Canada, 2025.

• Gamble J.-M., Shah B., Juurlink D.N., Kopp A., Nguyen L., and Paterson J.M., Risk of Hospital Presentation with Hypoglycemia Among Users of Beta-blockers with Diabetes: Population-Based Nested Case–Contr, Journal of General Internal Medicine, Volume 40, 3186-3193, Canada, 2025.

• Sharow A., Champigny J., Gamble J.-M., Houle S.K.D., Carter C., and Nagge J., The Comparative Effectiveness and Safety of Ambulatory Care Warfarin Management by Non-physician Providers Versus Usual Medical , Journal of Pharmacy Practice, Volume 38, 540-550, Canada, 2025.

• Maximos M., Pelletier R., Elsayed S., Maxwell C.J., Houle S.K.D., McConnell B., and Gamble J.-M., Unpacking Oral Challenge Protocols: A Descriptive Epidemiologic Study of Reactions, Predictors, and Practices for Delabeling Low, Hospital Pharmacy, Volume 60, 423-431, Canada, 2025.

• Gamble J.-M., Welk B., Clemens K.K., McArthur E., and Paterson J.M., Risk of hyperglycemia and new-onset diabetes among new users of medications for overactive bladder: population-based cohort stud, Drugs and Therapy Perspectives, Volume 41, 399-407, Canada, 2025.

• Chen Z., Gamble J.-M., Jantzi M., Hirdes J.P., and Lin J., Zero-Shot ATC Coding with Large Language Models for Clinical Assessments, Proceedings of the 2025 Annual Conference of the Nations of the Americas Chapter of the Association for Computational Linguistics Human Language Technologies Long Papers Naacl Hlt 2025, Volume 3, 226-232, Canada, 2025.

• Lau D., and Gamble J.-M., Suicidality among users of glucagon-like peptide-1 receptor agonists: An emerging signal?, Diabetes Obesity and Metabolism, Volume 26, 1150-1156, Canada, 2024.

• Maximos M., Maxwell C., and Gamble J.-M., Prescribing Trends for Oral Vancomycin and Fidaxomicin after Guideline and Formulary Changes in Ontario, Canada: An Interrupted , Canadian Journal of Hospital Pharmacy, Volume 77, Canada, 2024.

• Maximos M., Pelletier R., Elsayed S., Maxwell C.J., Houle S.K.D., McConnell B., and Gamble J.-M., A systematic review and meta-analysis of interventions to delabel low-risk penicillin allergies with consideration for sex and g, British Journal of Clinical Pharmacology, Volume 91, 684-697, Canada, 2024.

• Alkabbani W., Maxwell C.J., Marrie R.A., Tyas S.L., Lega I.C., and Gamble J.-M., Associations of Mid-and Late-Life Severe Hypoglycemic Episodes With Incident Dementia Among Patients With Type 2 Diabetes: A Pop, Diabetes Care, Volume 46, 331-340, Canada, 2023.